32 completed, 10 terminated, 5 recruiting, 4 not yet recruiting. 29 Phase 2, 21 Phase 1, 7 Phase 4, 5 Not applicable, 4 Early Phase 1.
Follow this drug Literature Review of Disulfiram trials Research Report on Disulfiram
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study Disulfiram 250 mg, Copper Gluconate 2 mg, Radiation Therapy - Thoracic Cancer | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2027-03-01 | 2026-09-28 |
| Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform Temozolomide, Disulfiram, Copper - Glioblastoma Multiforme | Phase 2 | Not yet recruiting | Olympion Medical Center | 32 | 2027-01-01 | 2025-05-25 |
| Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High Grade Glioma Disulfiram (DSF) - Brain (Nervous System) Cancers | Phase 1 | Not yet recruiting | Case Comprehensive Cancer Center | 20 | 2026-10-01 | 2026-09-28 |
| Disulfiram in Rheumatoid Arthritis Placebo, Disulfiram (DSF) - Rheumatoid Arthritis, Inflammation | Phase 2 | Not yet recruiting | University of Oklahoma | 20 | 2026-09-01 | 2026-07-27 |
| Disulfiram for Treatment of Retinal Degeneration Disulfiram 250 mg, Placebo - Inherited Retinal Dystrophy Primarily Involving Sensory Retina | Phase 1 / Phase 2 | Recruiting | University of Washington | 30 | 2026-05-03 | 2026-05-05 |
| A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma Methotrexate, Doxorubicin, Cisplatin - Osteosarcoma, Metastasis | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2026-03-11 | 2026-03-17 |
| Anxiety During Abstinence in AUD Disulfiram 250 mg, functional MRI - Alcohol Use Disorder | Early Phase 1 | Recruiting | Columbia University | 60 | 2025-09-15 | 2026-02-10 |
| The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration Oral disulfiram - Alcohol Use Disorder, Retinal Dystrophies | Phase 1 | Recruiting | University of Rochester | 15 | 2025-05-19 | 2026-09-16 |
| The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes Dapagliflozin 10mg Tab, Metformin 1000 mg (ttd), Placebo - Obesity, Dapagliflozin Adverse Reaction | Phase 4 | Active not recruiting | Oman Ministry of Health | 150 | 2024-04-22 | 2025-03-26 |
| Treatment of Advance Gastric Cancer With Disulfiram disulfiram and cisplatin, cisplatin - Chemotherapy；Advanced Gastric Cancer；Cisplatin；Disulfiram | Not applicable | Unknown | First People's Hospital of Hangzhou | 40 | 2023-06-01 | 2022-12-28 |
| Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas Disulfiram, Copper Gluconate, Liposomal Doxorubicin (Doxil) - Relapsed Sarcomas | Phase 1 | Recruiting | Case Comprehensive Cancer Center | 24 | 2023-03-09 | 2026-08-06 |
| Body Weight Response With Disulfiram in Humans Disulfiram 250 mg - Obesity; Drug | Early Phase 1 | Unknown | Universidad de Guanajuato | 10 | 2021-11-21 | 2021-12-17 |
| DISulfiram for COvid-19 (DISCO) Trial Disulfiram, Placebo - Covid19 | Phase 2 | Terminated | University of California, San Francisco | 11 | 2021-08-18 | 2023-09-13 |
| Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma Disulfiram, Copper Gluconate - Multiple Myeloma | Phase 1 | Terminated | University of Utah | 2 | 2021-05-21 | 2023-03-13 |
| Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19 Disulfiram, Placebo - Covid19 | Phase 2 | Completed | ETICA | 140 | 2020-11-20 | 2021-10-08 |
| Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder Perampanel Tablet, Disulfiram - Alcohol Disorders | Phase 1 / Phase 2 | Completed | Virginia Commonwealth University | 4 | 2020-10-15 | 2022-10-07 |
| Promoting Medications for Alcohol Use Disorder on the General Medicine Service audit and feedback, educational meetings, and academic detailing to promote medication receipt, Acamprosate, naltrexone, or disulfiram - Alcohol Use Disorder | Terminated | Yale University | 67 | 2020-01-01 | 2022-05-11 | |
| Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer. Disulfiram, Vinorelbin, Cisplatin - Metastatic Breast Cancer | Phase 2 | Withdrawn | National Cancer Institute, Slovakia | 2020-01-01 | 2023-10-06 | |
| Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine Safety Laboratories, AE Assessment, Physical Exam - Metastatic Pancreatic Cancer | Phase 2 | Terminated | HonorHealth Research Institute | 1 | 2019-10-17 | 2023-10-18 |
| Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease Disulfiram - Fatigue, Quality of Life | Phase 1 / Phase 2 | Completed | Research Foundation for Mental Hygiene, Inc. | 11 | 2019-07-31 | 2025-01-09 |
Showing 20 of 58. Sign in to see all of them.
Cocaine-Related Disorders (11) · Alcoholism (9) · Glioblastoma (7) · Alcohol-Related Disorders (4) · Opioid-Related Disorders (4) · HIV Infections (3) · Melanoma (3) · Obesity (3) · Acquired Immunodeficiency Syndrome (2) · Anxiety Disorders (2) · Breast Neoplasms (2) · COVID-19 (2) · Neoplasms (2) · Osteosarcoma (2) · Pancreatic Neoplasms (2)
Yale University (5) · University of California, San Francisco (4) · University of Arkansas (3) · University of Utah (3) · Baylor College of Medicine (2) · Case Comprehensive Cancer Center (2) · National Cancer Institute, Slovakia (2) · Sahlgrenska University Hospital (2) · Washington University School of Medicine (2) · Assistance Publique - Hôpitaux de Paris (1) · Columbia University (1) · Daniel George, MD (1) · ETICA (1) · Finnish Institute for Health and Welfare (1) · First People's Hospital of Hangzhou (1)
United States (41) · Australia (2) · Brazil (2) · Mexico (2) · Slovakia (2) · Sweden (2) · Argentina (1) · Canada (1) · China (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Greece (1)
Alison Oliveto, PhD (2) · Asgeir S Jakola, MD, PhD (2) · Jiayi Huang, M.D. (2) · Michal Mego, Prof (2) · Adriana Andrade, M.D. (1) · Albert Arias, MD, PhD (1) · Alejandro E Macias, MD (1) · Alison Oliveto, Ph.D. (1) · Aminah Jatoi, M.D. (1) · Asadullah Khan, MD (1) · Augusto Mota, MD/PhD (1) · Beatriz Y Hanaoka, MD, MSc (1) · Brian A Fallon, MD (1) · Damon Reed, MD (1) · Daniel George, MD (1)
PMID 35285015, PMID 24344045, PMID 38180268, PMID 18079068, PMID 21123942, PMID 22695473, PMID 22775772, PMID 23144826, PMID 23335901, PMID 26614966, PMID 30503034, PMID 30647912, PMID 32413333, PMID 32714562, PMID 33859430, PMID 33953123, PMID 33957901, PMID 34586085, PMID 34620071, PMID 34959641, PMID 37000452, PMID 38396172, PMID 38768767, PMID 40265182, PMID 42423707
P50DA018197 (2), R01DA013441 (2), K23AA030355 (1), K24AA016555 (1), K24AI069994 (1), P50DA009250 (1), P50DA012756 (1), R01CA195473 (1), R01DA012979 (1), R01DA019078 (1), R01DA024982 (1), R21AA026681 (1)